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Early diagnosis of breast cancer in high risk women
C.T.M. Brekelmans, C. Seynaeve, M.M.A. Tilanus, C.C.M. Bar­
tels, L.C. Verhoog, L.M.C. v.d. Bosch, J.G.M. Klijn
Committee fo r  Genetic and Medical Counselling, Rotterdam Can­
cer Institute, Rotterdam .
There is circumstantial evidence that population-based screen­
ing programmes for breast cancer can reduce mortality in women 
aged 50 to 70. However, the value of screening in younger women 
and/ or in high-risk groups such as women with a positive family 
history of breast cancer is unproven. In the meantime a rapidly 
increasing number of high-risk women are seeking counselling 
about potentially preventive measures such as screening. As for 
ethical reasons no randomized trials are to be expected, the effect 
of screening of these women must be evaluated by means of 
observational studies. First results from a number of specialized 
centres are now appearing. In general, these studies describe the 
potential of screening to detect tumours in a relatively early stage 
with a malignancy potential that is lower than clinical cancers.
In the Rotterdam Cancer institute a registration is being set up 
of high-risk women that are screened according to national guide­
lines, that include physical examination every six months and 
yearly mammography. Until date, 321 women were entered. Within 
a median follow-up time of 13.7 months, 5 tumours were detected.
These results suggest that selective screening of high-risk 
women might be effective. However, this conclusion is premature 
as, due to their observational character these studies might be 
subject to lead time, length and selection bias. While surrogate 
measures such as tumour stage may be useful as early indicators 
of the effect of screening, to date evidence on the ultimate 
endpoint, mortality, is lacking.
1 Hans F.A. Vasen, Internist, Medical Director, University Hos­
pital Leiden, Poortgebouw Zuid, Rijsburgerweg 10, 2333 A A 
Leiden, The Netherlands, e-mail: nfdht@xs4all.nl.
Measures of the effect of screening should include the extent 
of negative side effects such as the induction o f  tumours due to 
mammography and the detection o f  clinically insignificant cancers 
that would never have occurred in the absence of screening, as 
well as the impact on quality of life. Further, the cost-effective­
ness of different screening procedures should be assessed. These 
uncertainties indicate the need of carefully designed, large, 
prospective studies with a complete and sufficient foilow-up and a 
well-suited comparison group of unscreened women.
Magnetic resonance imaging of the breast
C. Boetes
Institute o f Radiology, Nijmegen University Hospital, Nijmegen
In the short time MR imaging o f  the breast has been utilized 
for clinical imaging, this technique has proven to be a valuable 
tool, which is able to supply unique information about the nature 
of various breast lesions.
MR imaging will play an increasingly important role in the 
evaluation of breast disease and is at the moment used as an 
additional tool to the conventional imaging techniques.
With the by us used sequence, namely the TurboFLASH 
sequence, not only a high sensitivity (95%) has been reached, but 
also a high specificity (86%).
Indications for MR imaging are the following. MR imaging is 
important in the selection for breast saving therapy, because MR 
imaging shows much better the extent of a malignant lesion than 
mammography. Evaluation of women treated with silicone im ­
plants is difficult with mammography but with MR imaging the 
whole breast can easily be investigated.
Also women who are strongly suspected of having breast 
cancer or who are at high risk for developing breast cancer, but 
who have equivocal mammographies due to very dense glandular 
tissue, will benefit from this technique.
0300-2977 /97 /$  15.00 © 1997 Elsevier Science B.V. All rights reserved. 
PII S 0 3 0 0 - 2 9 7 7 ( 9 7 ) 0 0 0 5 8 - 2
A2 Abstracts /Netherlands Journal o f Medicine 51 (1997) A1-A7
Until now breast studies have been performed using whole 
body systems with specially developed dedicated breast coils. The 
high costs of operating these machines and the limited availability 
prevent its use for breast imaging on a large scale, but with 
dedicated MR breast scanners easier accessibility and lower costs 
will be reached, so together with fast imaging sequences a high 
patient throughput becomes feasible.
Ataxia telangiectasia and high predisposition for cancer
A. Broeks *, A. F loor1, N, Russell2, F. van Leeuwen3, K. 
Jaspers 4, A. de Klein 4, and L. van’t Veer 1
1 Department o f  Experimental Therapy and Pathology, The
Netherlands Cancer institute, Amsterdam
2 Department o f  Radiotherapy, The Netherlands Cancer Institute, 
Amsterdam
Department o f  Epidemiology, The Netherlands Cancer Institute, 
Amsterdam
4 Department o f  Cell Biology and Genetics, Erasmus University, 
Rotterdam
The autosomal recessive disease Ataxia Telangiectasia (A-T) 
has been associated with an extremely high predisposition for 
cancer (more than 100-fold increase) and a high sensitivity of 
ionizing radiation. Individuals that have inherited one mutated 
allele of the Ataxia Telangiectasia gene (ATM) are known to be 
radiation sensitive and have a 1.9-fold increased risk for develop­
ing cancer (relative risk for breast cancer 3.9-fold). It is thought 
that 0.5% of the western population is heterozygous for ATM* and 
that 8% of all cases of breast cancer before age 40 can be 
attributed to ATM heterozygosity.
Recently, the ATM gene has been cloned and we have devel­
oped a protein truncation test (PTT) for rapid screening of frame- 
shift mutations of the coding region of the gene. In a first series of 
experiments we have established the mutation spectrum of ATM 
as present in Dutch Ataxia Telangiectasia patients. Fourteen dif­
ferent mutations in nine A-T patients have been identified using 
PTT that are scattered throughout the complete open reading 
frame. This indicates that there is no predominant Dutch ATM 
founder mutation, as is sometimes seen for other inherited (cancer) 
susceptibility genes.
Radiation exposure at young age is an established risk factor 
in development of breast cancer. Particularly, we have found that 
women treated for Hodgkin’s disease before age 20 with mantle- 
field irradiation have a 40-fold increased risk of developing breast 
cancer within the next 10-20 years. Also, patients who received 
radiotherapy before age 40 for treatment of breast cancer have a
2-3-fold increased risk for developing contralateral breast cancer 
within the next 10—20 years. The frequency of ATM heterozygos­
ity in these patient groups will be compared with the frequency in 
women that have been treated similarly and did not develop breast 
cancer. Thus, we can test the hypothesis that ATM heterozygous 
women have a disproportional high risk for developing radiation- 
induced breast cancer.
Clinical and genetic evaluation of ovarian cancer families
R.P. Zweemer, R.H.M. Verheijen, J.J.P. Gille, P.J. van Diest, G. 
Pals, F.H. Menko
Amsterdam Free University Hospital, Amsterdam
The purpose of the study was to determine the prevalence of 
BRCA1 and BRCA2 germline mutations among patients from 
ovarian cancer families and to evaluate age at diagnosis, histology 
and FIGO stage in the study group.
We reviewed 50 ovarian cancer patients from 30 ovarian 
cancer families. The 30 ovarian cancer families were subdivided 
into four groups based on the tumour type encountered and the 
pattern of disease in the family. (1) Hereditary breast and ovarian 
cancer (HBOC) and (2) hereditary ovarian cancer (HOC) were 
diagnosed when: (a) in the case of maternal transmission, at least 
three family members from two successive generations had a 
confirmed diagnosis of breast or ovarian cancer (or ovarian cancer 
only in HOC) in successive generations, one case being a first-de­
gree relative of the other two cases, or (b) in case of paternal 
transmission, at least two first-degree relatives and one (paternal) 
second-degree family member from two successive generations 
had confirmed breast or ovarian cancer (or ovarian cancer only in 
HOC), in successive generations, (3) familial breast and ovarian 
cancer (FBOC) and (4) familial ovarian cancer (FOC) were 
diagnosed in the event of familial clustering of these tumour types 
if the pedigree data did not fulfill the criteria for either HBOC of 
HOC.
We compared relevant clinical characteristics with those of a 
cancer registry group. BRCA1 (exons 2-24) and BRCA2 (exon 
11) germline mutation detection was performed by a protein 
truncation test and sequencing of BRCA1 exon 2 (185delAG 
mutation).
Ten (40%) of 25 families tested revealed a germline BRCA1 
or BRCA2 mutation. Mutations were detected in 6 of 12 (50%) 
HBOC families in 3 or 8 (38%) of FBOC, and 1 of 5 (20%) of 
FOC families. Patients with ovarian cancer from the study group 
had significantly lower age at diagnosis with a mean age of 54.3 
(range 31-77) compared to 62.4 (range 14-98) in the cancer 
registry group. In the study group a significantly higher proportion 
of patients was diagnosed with an advanced (III or IV) FIGO 
stage. Finally the study group showed a relatively high frequency 
of serous adenocarcinoma.
Prognosis of patients with hereditary non-polyposis colorectal 
cancer as compared to patients from the general population
P. van’t V eer1, L.M.C. van den Bosch1, C.H.F. Gimbrere 2,
D.W. Voskuil \  H.F.A. Vasen2
1 Department o f Epidemiology and Public Health, Wageningen
Agricultural University, Wageningen
2 Comprehensive Cancer Centre Middle Netherlands, Utrecht
3 Foundation fo r  the Detection o f Hereditary Tumours, Leiden
Several investigators have suggested a favorable survival for 
patients with Hereditary Non-Polyposis Colorectal Cancer
